Transcatheter mitral valve implantation (TMVI) using the Edwards FORTIS device.

Abstract

Transcatheter aortic valve implantation (TAVI) has demonstrated the feasibility of treating valvular heart disease with transcatheter therapy. On the back of this success, various transcatheter concepts are being evaluated to treat other valvular disease, especially mitral regurgitation (MR). The concepts currently approved to treat MR replicate surgical mitral valve repair. However, most of them cannot eliminate MR completely. Similar to TAVI, a transcatheter mitral valve implantation may provide a valuable alternative. The FORTIS transcatheter mitral valve (Edwards Lifesciences, Irvine, CA, USA) is a self-expanding device implanted via a transapical approach. We describe our experience and early results in the first five patients treated on compassionate grounds. We also describe the details of the device, selection criteria and technical details of implantation.

• Authors: Vinayak Bapat, Lutz Buellesfeld, Mark D Peterson, Jane Hancock, David Reineke, Chris Buller, Thierry Carrel, Fabien Praz, Ronal Rajani, Neil Fam, Han Kim, Simon Redwood, Christopher Young, Christopher Munns, Stephan Windecker, Martyn Thomas
• Journal: EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology (EuroIntervention) Vol. 10 Suppl U Pg. U120-8 (Sep 2014) ISSN: 1969-6213 [Electronic] France
• PMID: 25256325 (Publication Type: Journal Article)

Topics

• Animals
• Bioprosthesis
• Cattle
• Endovascular Procedures (instrumentation, methods)
• Heart Valve Prosthesis
• Heart Valve Prosthesis Implantation (instrumentation, methods)
• Humans
• Mitral Valve
• Mitral Valve Insufficiency (surgery)